Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · July 13, 2016

Angiotensin II Antagonist Treatment With Candesartan in Patients With Early Breast Cancer

JAMA Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Oncology
Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer
JAMA Oncol 2016 Jun 23;[EPub Ahead of Print], AH Boekhout, JA Gietema, BM Kerklaan, et al

Further Reading